|
Originally published In Press as doi:10.1074/jbc.M105192200 on October 11, 2001
J. Biol. Chem., Vol. 276, Issue 52, 49053-49060, December 28, 2001
MDR1 P-glycoprotein Reduces Influx of Substrates
without Affecting Membrane Potential*
Gary D.
Luker §,
Thomas P.
Flagg¶,
Qun
Sha¶ ,
Kathryn E.
Luker §,
Christina M.
Pica §,
Colin G.
Nichols¶, and
David
Piwnica-Worms §**
From the Molecular Imaging Center, Mallinckrodt
Institute of Radiology, and the Departments of § Molecular
Biology and Pharmacology and ¶ Cell Biology and Physiology,
Washington University School of Medicine,
St. Louis, Missouri 63110
MDR1
(multidrug resistance)
P-glycoprotein (Pgp; ABCB1) decreases intracellular concentrations of
structurally diverse drugs. Although Pgp is generally thought to be an
efflux transporter, the mechanism of action remains elusive. To
determine whether Pgp confers drug resistance through changes in
transmembrane potential (Em) or ion conductance, we
studied electrical currents and drug transport in Pgp-negative MCF-7
cells and MCF-7/MDR1 stable transfectants that were
established and maintained without chemotherapeutic drugs. Although
Em and total membrane conductance did not differ
between MCF-7 and MCF-7/MDR1 cells, Pgp reduced
unidirectional influx and steady-state cellular content of
Tc-Sestamibi, a substrate for MDR1 Pgp, without
affecting unidirectional efflux of substrate from cells. Depolarization
of membrane potentials with various concentrations of extracellular
K+ in the presence of valinomycin did not inhibit the
ability of Pgp to reduce intracellular concentration of Tc-Sestamibi,
strongly suggesting that the drug transport activity of
MDR1 Pgp is independent of changes in
Em or total ion conductance. Tetraphenyl borate, a
lipophilic anion, enhanced unidirectional influx of Tc-Sestamibi to a
greater extent in MCF-7/MDR1 cells than in control cells,
suggesting that Pgp may, directly or indirectly, increase the positive
dipole potential within the plasma membrane bilayer. Overall, these
data demonstrate that changes in Em or macroscopic
conductance are not coupled with function of Pgp in multidrug
resistance. The dominant effect of MDR1 Pgp in this system
is reduction of drug influx, possibly through an increase in
intramembranous dipole potential.
*
This study was supported by National Institutes of Health
Grant HL03683 and Department of Energy Grant ER61885.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Dept. of Medicine, University of Maryland
Medical System, Baltimore, MD 21201.
**
To whom correspondence should be addressed: Molecular Imaging
Center, Mallinckrodt Inst. of Radiology, Washington University School
of Medicine, P. O. Box 8225, 510 S. Kingshighway Blvd., St. Louis, MO
63110. Tel.: 314-362-9359; Fax: 314-362-0152; E-mail: piwnica-wormsd@mir.wustl.edu.
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. A. Dubikovskaya, S. H. Thorne, T. H. Pillow, C. H. Contag, and P. A. Wender
Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters
PNAS,
August 26, 2008;
105(34):
12128 - 12133.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms
Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier
J. Nucl. Med.,
February 1, 2005;
46(2):
354 - 364.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|